Holen Sie sich die Stockscreener-App
24.46
0.82%
0.225
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$24.24
Offen:
$24.275
24-Stunden-Volumen:
2.10M
Relative Volume:
0.04
Marktkapitalisierung:
$138.15B
Einnahmen:
$62.46B
Nettoeinkommen (Verlust:
$7.88B
KGV:
17.73
EPS:
1.38
Netto-Cashflow:
$11.22B
1W Leistung:
+0.53%
1M Leistung:
+4.04%
6M Leistung:
-7.89%
1J Leistung:
-13.40%
1-Tages-Spanne:
$24.26
$24.45
1-Wochen-Bereich:
$24.07
$24.44
52-Wochen-Spanne:
$20.91
$31.54
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
24.45 | 138.15B | 62.46B | 7.88B | 11.22B | 1.38 |
|
LLY
Lilly Eli Co
|
780.87 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
153.61 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
68.43 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
185.50 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
122.47 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer Secures Global Licensing Rights Outside China for 3SBio’s PD-1 and VEGF Targeting Antibody SSGJ-707 - geneonline.com
Transcript : Pfizer Inc.Special Call - MarketScreener
Is Pfizer Stock a Buy for Its Massive 7% Dividend Yield? A Trader’s Look - Daily Chhattisgarh News
Pfizer Secures Global Licensing Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707 - geneonline.com
Global Drugmakers Tap Chinese Biotech for Novel Cancer Therapies - Caixin Global
Lawmakers refresh tax-dodging accusations against Big Pharma, targeting Pfizer, AbbVie and others - Fierce Pharma
Pfizer’s $6.15B 3Sbio deal tops May’s biopharma activity - BioWorld MedTech
Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan - CNBC
Should Value Investors Buy Pfizer (PFE) Stock? - Nasdaq
Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer - CNBC
Pfizer Secures Global Rights Outside China for 3SBio’s Dual-Target Cancer Therapy SSGJ-707 - geneonline.com
Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail
Pfizer CEO Mentioned No Drug Price Commitments by Pfizer Inc. (PFE) - MSN
Pfizer Inc. (NYSE:PFE) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock? - Yahoo Finance
Goldman Sachs Maintains a Hold Rating on Pfizer (NYSE:PFE), Retains $27 PT - Insider Monkey
Pfizer (PFE) Stock: Analyst Targets Suggest 15% Upside as Company Touts Strong Margins and Dividend - Daily Chhattisgarh News
FDA Denies Pfizer's (PFE) Label Expansion for Talzenna in Prosta - GuruFocus
Pfizer bid to expand Talzenna label faces FDA snub (PFE:NYSE) - Seeking Alpha
Pfizer Secures Global Licensing Rights for 3SBio’s Dual-Target Cancer Therapy Excluding China - geneonline.com
Pfizer (PFE) Option Activity Shows Mixed Sentiment | PFE Stock N - GuruFocus
Pfizer’s SWOT analysis: stock outlook amid pipeline progress, cost cuts - Investing.com
Pfizer : Provides Update on U.S. Regulatory Review of TALZENNA in Combination with XTANDI for Broader Use in Metastatic Castration-Resistant Prostate Cancer - MarketScreener
Young minds dive into discovery at Pfizer School of Science Mobile Experience - Yahoo
Pfizer’s 2024 Impact Report Highlights Accomplishments in Sustainability, Responsibility - Pfizer
BioNTech’s CureVac Deal Signals Deep Pivot Toward mRNA Cancer Therapies - Investing.com
Pfizer (PFE) Stock Shows Strong Rebound with Over 8% Monthly Gain, Halting Longer-Term Slide - Daily Chhattisgarh News
Graft vs Host Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharma, Regimmune Corp - The Globe and Mail
PFIZER INC : UBS remains Neutral - MarketScreener
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.’s Board Of Directors For ... - Bluefield Daily Telegraph
Why Apple, Microsoft, Pfizer and other U.S. multinational corporations set up shop in Ireland - CNBC
4 Cheap Dividend Stocks Under $50 That Keep Raising Payouts - 24/7 Wall St.
Pfizer (PFE) Sees Mixed Options Sentiment Amidst Modest Share In - GuruFocus
Kennedy replaces fired US CDC panel members, includes anti-vaccine proponents - marketscreener.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Pfizer Scraps Bid for Depo-Provera Mass Tort Following Dismissal of Most Phila. Plaintiffs - Law.com
Cantor Fitzgerald Remains a Hold on Pfizer (PFE) - The Globe and Mail
Pfizer says drugmakers met with Trump admin to discuss lowering drug prices - Yahoo Finance
Request for Proposals: Pfizer Independent Research Grant Program 2025 - fundsforNGOs
10 Best Wide Moat Stocks To Buy Now - Insider Monkey
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors - The Globe and Mail
Why China Biotech Is Getting a DeepSeek Moment, Too - Bloomberg.com
Pfizer Settles With Final Defendant in Mektovi Patent Lawsuit - Bloomberg Law News
Pfizer Stock Rallies Over 8% in a Month, but Faces Long-Term Headwinds - Daily Chhattisgarh News
Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.’s Firing of Vaccine Advisors. - Barron's
Top Cancer Stocks to Supercharge Your 2025 Portfolio - Yahoo Finance
Wall Street Analysts Love These Ultra-High Yield Dividend Stocks - 24/7 Wall St.
Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up - marketscreener.com
Cantor Fitzgerald holds Pfizer stock at Neutral with $24 target By Investing.com - Investing.com India
Pfizer: Dividend Investor's Dream And Patent Cliff Nightmare (NYSE:PFE) - Seeking Alpha
No drug price pledges by Pfizer, others in talks with US government, Pfizer CEO says - Reuters
Pfizer CEO Reportedly Says Company Made No Drug Price Pledges In Meeting With Trump Administration: Retail Sentiment Improves By Stocktwits - Investing.com India
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):